VivoSeq
Ophthalmology

Choroidal Neovascularization

23

Pipeline Programs↗

3

Active Trials↗

10

Companies Involved↗

Choroidal Neovascularization is an emerging landscape with 23 programs across 10 companies. The most active players are AnewPharma, Mateon Therapeutics, Pfizer. 4 therapies are approved with 6 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

48/100

Pipeline Velocity

0/100

Mech. Concentration

20/100

Completion Rate

79/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

AnewPharma

1 program

Phase 1M

Mateon Therapeutics

1 program

Phase 2Pfizer logo

Pfizer

1 program

Phase 2C

Chengdu Kanghong Biotech Co., Ltd.

1 program

Phase 2Roche logo

Roche

3 programs

Phase 2Regeneron logo

Regeneron

2 programs

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

26programs
Small molecule1558%
Monoclonal antibody935%
Protein / enzyme28%

Modality classified for 100% of 26 pipeline programs.

Analysis

Trial Status

38

clinical trials

Completed22 · 58%
Unknown status7 · 18%
Withdrawn3 · 8%
Terminated2 · 5%
Not yet recruiting1 · 3%
Suspended1 · 3%
Other2 · 5%

Clinical Trials

Trial Activity

38 trials

Biomarkers Analysis of Mineralocortoid Receptor Activation in the Serum and Ocular Fluid of Patients With Choroidal Neovascularization
Recruiting·IInstitut National de la Santé Et de la Recherche Médicale, France·N/A·NCT04439708·250 enrolled
A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia
Active, not recruiting·Roche logoRoche·Phase 3·NCT06176352·280 enrolled
The Treatment Burden of Myopic Choroidal Neovascularization
Not yet recruiting·PPoliclinico Gaspare Rodolico - San Marco Catania·N/A·NCT07009574·100 enrolled
Initial Treatment With Bevacizumab in Choroidal Neovascularization Associated to High Myopia
Completed·IInstituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA·Phase 3·NCT01716026·66 enrolled
Safety and Efficacy Study of Combretastatin A4 Phosphate to Treat Patients With Choroidal Neovascularization Secondary to Pathologic Myopia
Completed·MMateon Therapeutics·Phase 2·NCT01423149·23 enrolled
Special Drug Use Investigation of EYLEA for Myopic Choroidal Neovascularization
Completed·Bayer logoBayer·N/A·NCT02260687·353 enrolled
Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization
Completed·Novartis logoNovartis·Phase 3·NCT00436553·321 enrolled
Reduced-fluence Verteporfin Photodynamic Therapy Plus Ranibizumab for Choroidal Neovascularization in Pathologic Myopia
Completed·UUniversity of Campania Luigi Vanvitelli·Phase 1·NCT01968486·60 enrolled
A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia.
Completed·Novartis logoNovartis·Phase 3·NCT02034006·200 enrolled
Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial
Completed·JJohns Hopkins University·Phase 1·NCT00363168·7 enrolled
SD-OCT-guided Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Myopia
Completed·VVista Klinik·Phase 4·NCT03409250·20 enrolled
Intravitreal Conbercept Injection in Patients With Myopic Choroidal Neovascularization
Completed·ZZhongshan Ophthalmic Center, Sun Yat-sen University·N/A·NCT03971162·50 enrolled
Efficacy of Aflibercept (Eylea®) on Choroidal Neovascularization (Type 3)
Completed·PPoitiers University Hospital·Phase 4·NCT02320474·26 enrolled
Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia
Completed·Novartis logoNovartis·Phase 3·NCT01922102·457 enrolled
Dosing Strategy of Intravitreal Ranibizumab for Pathological Myopia Choroidal Neovascularization
Completed·ZZhongshan Ophthalmic Center, Sun Yat-sen University·Phase 4·NCT03042871·54 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)